Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965474 | 0.98 | HRH3 (0.56) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4420612 | 0.93 | MAPT (0.61) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4416469 | 0.91 | HRH3 (0.61) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL967274 | 0.84 | — | — | |
| SCHEMBL968654 | 0.82 | HRH3 (0.48) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL17393158 | 0.79 | KEAP1 (0.54) | HRH3CYP1A2MAPK1SMN1; SMN2POLB | |
| SCHEMBL146416 | 0.75 | MAPT (0.86) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL15485592 | 0.75 | HRH3 (0.52) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL678405 | 0.75 | HRH3 (0.52) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL4416552 | 0.75 | PAOX (0.50) | HRH3MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| CN-105073715-B | The derovatives of dihydrogen dazin 3,5 | 中外制药株式会社 | 2017-12-01 | — | — | CN | disclosed |
| CN-107072993-A | Medicine containing sodium dependence phosphate transporter inhibitor | 中外制药株式会社 | 2017-08-18 | — | — | CN | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20110160251-A1 | ANIMAL ECTOPARASITE CONTROL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| CN-102036951-A | Nitrile compound and its use for control of arthropod pest | SUMITOMO CHEMICAL CO | 2011-04-27 | — | — | CN | disclosed |
| US-20110021627-A1 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2265569-A2 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | Sumitomo Chemical Company, Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| CN-101790511-A | Halogen-containing organosulfur compounds and uses thereof | SUMITOMO CHEMICAL CO | 2010-07-28 | — | — | CN | disclosed |
| WO-2010074327-A1 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUNDS AND USE THEREOF FOR CONTROLLING ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160422-A1 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2162429-A2 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009116687-A2 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009005110-A2 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021627-A1 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST | C5, OR10J3, NOX3 | HRH3 241/4885MAPT 4575/4885CYP1A2 385/4885 |
| US-20110160251-A1 | ANIMAL ECTOPARASITE CONTROL COMPOSITION | ADIPOR1, ADIPOR2, PLIN3 | HRH3 3479/4885MAPT 3152/4885CYP1A2 1206/4885 |
| US-20100160422-A1 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | C5, C1S, C9 | HRH3 82/4885MAPT 4801/4885CYP1A2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.